omniture

LORATI Successfully Develops An Effective Treatment for AIDS -- A Big Medical Breakthrough in Human History

A powerful new drug has been successfully developed to target on 35+ million people living with HIV/AIDS globally
2015-07-14 08:30 3793

TAICHUNG, July 14, 2015 /PRNewswire/ -- Lorati Company Limited, a Taiwan-based biotechnology and skincare company, today announced that it has successfully developed nano-medication, which can effectively inhibit HIV-1 viral replication.

Lorati CEO, David Lo, said nano-medication, based on bentonite, also known as God's dirt, is believed to be the last-ditch treatment for AIDS. Unbelievable improvement can be obtained within one month of treatment by nano-medication. After being treated by a couple of months, AIDS patients can even go back to HIV-1 status, meaning, number of CD4+ increases substantially.

According to a test report from The Johns Hopkins University School of Medicine, nano-medication can 100% inhibit replication of HIV-1 in vitro.  "No existing drug and/or regiment of drugs for HIV-1/AIDS can achieve the same performance," said Mr. Lo.

Furthermore, it has been scientifically verified that nano-medication does not cause any side effects. Neither does it have drug resistance issue. "If AIDS patients want to be out of critical condition, nano-medication is the only resort," said Mr. Lo.

Mr. Lo explained, "Nano-medication can tackle HIV-1 both extracellularly and intracellularly."  Nano-particles of nano-medication can bond to HIV-1 spikes, meaning glycoprotein 120 (gp120) and glycoprotein 41 (gp41), which are polar chemicals. Since gp120 contains 50% of glycans, it is extremely difficult for organic medicine to bond to it.

Bonding between gp120/gp41 and human cell's receptors is van der Waals force or static force. However, bond between nano-particles and gp120/gp41 is ionic bonding. With stronger force in ionic bonding, nano-medication will prevent HIV-1 from attaching to human cell's receptors. As a result, CD4+, CCR5, CXCR4, and HIV-1 can't infect human cells and reproduce its progeny, which will kill HIV-1 extracellularly.

Mr. Lo further explained, nano-particles of nano-medication, through caveolae, can enter the cytosol. These nano-particles will then bond to the enzymes required for HIV-1 replication. They will function like various inhibitors to invalidate enzymes required for HIV-1 replication, such as PI (protease inhibitor), NNRTI (non-nucleoside reverse transcriptase inhibitors), etc. Through this process, nano-particles will stop HIV-1 from replicating.

In addition, when nano-particles meet with HIV-1 (HIV-1 spikes and enzymes), it is physical reaction. Based on this fact, nano-medication will not cause mutations in HIV-1.

Delirium is the most common cognitive disorder in hospitalized patients with AIDS. Usually, one year prior to AIDS patients pass away, HIV-1 will attack their brain which explains the cause of the cognitive disorder.  "No existing drug or medication in the world can tackle HIV-1 in the brain due to blood-brain-barrier (BBB).  Thus far, only nano-medication can overcome BBB as evidenced by successful treatment of brain cancer," said Mr. Lo.

"Nano-medication, in some way, certifies the statement, God formed man out of dirt from the ground," said Mr. Lo.

The company is now looking for strategic partners to conduct clinical trials on AIDS, and is open for discussion with regard to any forms of collaboration.

Contact: 
Lorati Company Ltd.
Mr. David Lo
Tel: +886-912-549-632 / +886-4-2483-0545
Email: david@lorati.com.tw  
Website: www.lorati.com.tw

Source: Lorati Company Ltd.
collection